Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07118176 · ClinicalTrials.gov registry record · Phase 1

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

A Phase 1 study of Breast Carcinoma and Hematopoietic and Lymphatic System Neoplasm, sponsored by Jonsson Comprehensive Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT07118176 is a Phase 1 study of Breast Carcinoma and Hematopoietic and Lymphatic System Neoplasm that is actively recruiting participants, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 30 participants, below the 770-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07118176, a Phase 1 study of Breast Carcinoma and Hematopoietic and Lymphatic System Neoplasm, is actively recruiting participants, sponsored by Jonsson Comprehensive Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This phase I trial is evaluating a new imaging tracer (68Ga-FAPi-46) with positron emission tomography (PET)/computed tomography (CT) to determine where and to which degree the tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues (the biodistribution) in patients with solid tumors or hematologic (blood) cancers. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 68Ga-FAPi-46. Because some cancers take up 68Ga-FAPi-46, it can be seen with PET. CT utilizes x-rays that traverse the body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in a patient's body. Combining a PET scan with a CT scan can help make the image easier to interpret. PET/CT scans are hybrid scanners that combine both modalities into a single scan during the same examination.

Interventions

  • PROCEDURE Computed Tomography
  • PROCEDURE Positron Emission Tomography
  • OTHER Fludeoxyglucose F-18
  • RADIATION Gallium Ga 68 FAPi-46

Study Locations (1)

California

  • UCLA / Jonsson Comprehensive Cancer Center - Los Angeles

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-08-01
Est. Completion 2027-09-07
Phase Phase 1

Sponsor

Jonsson Comprehensive Cancer Center

321 total trials

What the Registry Record Tells You About NCT07118176

The ClinicalTrials.gov registry entry for NCT07118176 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 770-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (96% lower). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Breast Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Computed Tomography is the first listed.

NCT07118176 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT07118176 about?

NCT07118176 is a clinical study titled "Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers". This phase I trial is evaluating a new imaging tracer (68Ga-FAPi-46) with positron emission tomography (PET)/computed tomography (CT) to determine where and to which degree the tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues (the biodistribution) in patients with solid tumors or hemat...

What is the current status of trial NCT07118176?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-08-01. Estimated completion is 2027-09-07.

What conditions does trial NCT07118176 study?

This clinical trial studies the following conditions: Breast Carcinoma, Hematopoietic and Lymphatic System Neoplasm, Cholangiocarcinoma, Colorectal Carcinoma, Head and Neck Carcinoma.

What interventions are being tested in trial NCT07118176?

The interventions under investigation include: Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), Fludeoxyglucose F-18 (OTHER), Gallium Ga 68 FAPi-46 (RADIATION).

Who is sponsoring clinical trial NCT07118176?

This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07118176 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.